Literature DB >> 26042542

Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.

Mauro Ravera1, Elisabetta Gabano1, Ilaria Zanellato1, Ilaria Bonarrigo1, Manuela Alessio1, Fabio Arnesano2, Angela Galliani2, Giovanni Natile2, Domenico Osella3.   

Abstract

A series of Pt(IV) anticancer prodrug candidates, having the equatorial arrangement of cisplatin and bearing two aliphatic carboxylato axial ligands, has been investigated to prove the relationship between lipophilicity, cellular accumulation, DNA platination and antiproliferative activity on the cisplatin-sensitive A2780 ovarian cancer cell line. Unlike cisplatin, no facilitated influx/efflux mechanism appears to operate in the case of the Pt(IV) complexes under investigation, thus indicating that they enter by passive diffusion. While Pt(IV) complexes having lipophilicity comparable to that of cisplatin (negative values of log Po/w) exhibit a cellular accumulation similar to that of cisplatin, the most lipophilic complexes of the series show much higher cellular accumulation (stemming from enhanced passive diffusion), accompanied by greater DNA platination and cell growth inhibition. Even if the Pt(IV) complexes are removed from the culture medium in the recovery process, the level of DNA platination remains very high and persistent in time, indicating efficient storing of the complexes and poor detoxification efficiency.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell growth inhibition; Cellular accumulation; DNA platination; Lipophilicity; Pt(IV) complexes

Mesh:

Substances:

Year:  2015        PMID: 26042542     DOI: 10.1016/j.jinorgbio.2015.05.012

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  7 in total

1.  Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs to Escherichia coli.

Authors:  Chuchu Guo; Elizabeth M Nolan
Journal:  J Am Chem Soc       Date:  2022-07-08       Impact factor: 16.383

2.  Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes.

Authors:  Mauro Ravera; Elisabetta Gabano; Ilaria Zanellato; Elena Perin; Aldo Arrais; Domenico Osella
Journal:  Bioinorg Chem Appl       Date:  2016-09-28       Impact factor: 7.778

3.  Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.

Authors:  Vojtech Novohradsky; Ilaria Zanellato; Cristina Marzano; Jitka Pracharova; Jana Kasparkova; Dan Gibson; Valentina Gandin; Domenico Osella; Viktor Brabec
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

4.  A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.

Authors:  Beatrice Ferrari; Elisa Roda; Erica Cecilia Priori; Fabrizio De Luca; Angelica Facoetti; Mauro Ravera; Federico Brandalise; Carlo Alessandro Locatelli; Paola Rossi; Maria Grazia Bottone
Journal:  Front Neurosci       Date:  2021-03-22       Impact factor: 4.677

5.  Facile Synthesis of a Pt(IV) Prodrug of Cisplatin and Its Intrinsically 195mPt Labeled Analog: A Step Closer to Cancer Theranostic.

Authors:  K Shitaljit Sharma; K V Vimalnath; Prasad P Phadnis; Rubel Chakravarty; Sudipta Chakraborty; Ashutosh Dash; Rajesh K Vatsa
Journal:  Indian J Nucl Med       Date:  2021-06-21

6.  Unveiling the anti-cancer mechanism for half-sandwich and cyclometalated Ir(iii)-based complexes with functionalized α-lipoic acid.

Authors:  Meng-Meng Wang; Xu-Ling Xue; Xi-Xi Sheng; Yan Su; Ya-Qiong Kong; Yong Qian; Jian-Chun Bao; Zhi Su; Hong-Ke Liu
Journal:  RSC Adv       Date:  2020-02-03       Impact factor: 4.036

7.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action.

Authors:  Raji Raveendran; Jeremy Phillip Braude; Ezequiel Wexselblatt; Vojtech Novohradsky; Olga Stuchlikova; Viktor Brabec; Valentina Gandin; Dan Gibson
Journal:  Chem Sci       Date:  2016-01-15       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.